Major Depressive Disorder

Two pharmaceutical firms announced they have started a phase 2/3 trial to evaluate the efficacy of ulotaront, a trace amine-associated receptor 1 agonist, as an adjunctive therapy for major depressive disorder treatment, according to a joint press release.

The FDA has issued a “study may proceed” letter to biopharmaceutical company Vistagen for its newly filed investigational new drug application for the clinical development of PH10, a treatment for major depressive disorder.

EmbarkNeuro, a neuroscience biotech company formerly known as Ancora Bio, announced its phase 2 trial is under way for ANC-501, a first-in-class vasopressin 1b receptor antagonist for the treatment of major depressive disorder.

A 25 mg dose of psilocybin was associated with improvements in treatment-resistant depression over a 3-week period, but with adverse events, a recent study found.

Arrivo BioVentures, a biopharmaceutical company, has announced preliminary results from a randomized, placebo-controlled phase 2 clinical trial of SP-624, a first-in-class, sirtuin 6 activator for the treatment of major depressive disorder.

NMDA-receptor partial agonist D-cycloserine enhanced transcranial magnetic stimulation treatment outcomes in those with major depressive disorder, researchers reported.

Adolescents with subclinical hypothyroidism do not have an increased risk for major depressive disorder compared with those with normal thyroid function, according to a study published in Thyroid.

In individuals with major depressive disorder and childhood trauma, symptoms improved significantly following pharmacological and psychotherapeutic treatments, regardless of severity, per a study published in Lancet Psychiatry.

The FDA has granted breakthrough device designation to Magnus Medical for its neuromodulation treatment of major depressive disorder in adults who failed to achieve improvement from previously prescribed antidepressants.

Introducing electroconvulsive therapy earlier in a treatment course for major depressive disorder or bipolar disorder may lead to improvements in clinical outcomes, according to a study published in the Journal of Clinical Psychiatry.